CD44 and ovarian cancer: In present study, we confirmed that the mRNA and protein expression of CD44 were both significantly decreased in comparison with the untransfected cells, which indicated that CD44 gene may be a candidate therapeutic target for ovarian cancer, and using PEG-MZF-NPs to transfer objective gene in gene therapy is workable.